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AKT kinase, also known as protein kinase B, is a key regulator
of cell growth, proliferation, and metabolism. The activation of
the AKT signaling pathway is one of the most frequent molecu-
lar alterations in a wide variety of human cancers. Dickson and
coworkers recently observed that Ca2calmodulin (Ca2CaM)
may be a common regulator of AKT1 activation (Deb, T. B.,
Coticchia, C. M., and Dickson, R. B. (2004) J. Biol. Chem. 279,
38903–38911). In our efforts to scan the mRNA-displayed pro-
teome libraries for Ca2CaM-binding proteins, we found that
both human and Caenorhabditis elegans AKT1 kinases bound
to CaM in a Ca2-dependent manner (Shen, X., Valencia, C. A.,
Szostak, J., Dong, B., and Liu, R. (2005) Proc. Natl. Acad. Sci.
U. S. A. 102, 5969–5974 and Shen, X., Valencia, C. A., Gao, W.,
Cotten, S. W., Dong, B., Chen, M., and Liu, R. (2007) submitted
for publication). Here we demonstrate that Ca2CaM and
human AKT1 were efficiently co-immunoprecipitated, and
their interaction was direct rather than mediated by other pro-
teins. The binding is in part attributed to the first 42 residues of
the pleckstrin homology (PH) domain, a region that is critical
for the recognition of its lipid ligands. The PHdomain of human
AKT1 can disrupt the complex of the full-length AKT1 with
Ca2CaM. In addition,Ca2CaMcompeteswith phosphatidyl-
inositol 3,4,5-trisphophate for interaction with the PH domain
of humanAKT1.Our findings suggest that Ca2CaM is directly
involved in regulating the functions of AKT1, presumably by
releasing the activated AKT1 from the plasma membrane
and/or prohibiting it from re-association with phosphoinositi-
des on plasma membrane.
AKT3 was originally discovered as an oncogene transduced
by the acute transforming retrovirus (4, 5). It is now known to
include a family of three closely related members, namely
AKT1, AKT2, and AKT3, each encoding a highly conserved
serine/threonine protein kinase homolog (6, 7). The three AKT
isoforms differ slightly in the localization of their regulatory
phosphorylation sites. AKT1 is predominant in most tissues;
AKT2 is highly expressed in insulin-responsive tissues; whereas
AKT3 is abundant in brain tissues. AKTkinases consist of three
conserved domains, including a pleckstrin homology (PH)
domain at the N terminus, a kinase catalytic domain at the
center, and a regulatory hydrophobic motif containing domain
at the C terminus (8). The N-terminal PH domain spans from 1
to 107 amino acids and is 80% identical among the AKT iso-
forms. The central catalytic domain is 90% identical among
the AKT isoforms and is closely related to protein kinase A,
protein kinase C, glycogen synthase kinase-3, and S6 subfami-
lies of the AGCkinase family. This central domain catalyzes the
phosphorylation of numerous AKT downstream substrates,
including p21, glycogen synthase kinase-3, Bad, Forkhead,
caspase-9, IKK, andMdm2 (9–22). TheC-terminal extension is
70% identical among the three AKT isoforms and is most
closely related to the protein kinaseC family. It appears that this
extension domain wraps around the front of the ATP binding
pocket and interacts through a regulatory hydrophobic motif
with a pocket at the back of the kinase domain.
The signaling pathway of AKT starts from the activation of
phosphatidylinositol 3-kinase through binding of a growth
factor to a receptor tyrosine kinase (23–26). The activated
phosphatidylinositol 3-kinase converts membrane-bound
PtdIns(3,4)P2 to PtdIns(3,4,5)P3. The PH domain of AKT then
interacts with PtdIns(3,4,5)P3, which results in anchoring the
AKTkinase to the plasmamembrane, where it undergoes phos-
phorylation and activation by 3-phosphoinositide-dependent
protein kinase-1, the rictor-mammalian target of rapamycin
complex, and probably other kinases (27, 28). AKT is fully acti-
vated following its phosphorylation at two regulatory residues,
which are structurally and functionally conserved within the
AGC kinase family. These residues include a threonine residue
on the kinase catalytic domain (Thr-308, Thr-309, andThr-305
for AKT1, AKT2, and AKT3, respectively) and a serine residue
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on the hydrophobic motif (Ser-473, Ser-474, and Ser-472 for
AKT1,AKT2, andAKT3, respectively). Such activation permits
a conformational change that results in substrate binding and a
significant increase of the rate of catalysis.
AKT familymembers regulate a wide variety of cellular func-
tions, including apoptosis, cellular proliferation, differentia-
tion, intermediary metabolism, genome stability, and neo-vas-
cularization (25, 27). The regulation mechanism of AKT is by
deactivation or activation of its downstream substrates through
phosphorylation. For instance, AKT kinase facilitates growth
factor-mediated cell survival and blocks apoptotic cell death by
phosphorylating and deactivating pro-apoptotic factors such as
Bad, caspase-9, and Forkhead transcription factors (9, 14–19).
AKT also phosphorylates and inactivates glycogen synthase
kinase-3, which allows the activation of glycogen synthase (13).
On the other hand, AKT phosphorylates and activates IKK,
which phosphorylates IB followed by its ubiquitination and
proteasomal degradation (20–22, 29). AKT regulatesmany cel-
lular processes that, upon deregulation, may contribute to the
development or progression of cancer. It is now evident that the
activation of the AKT signaling pathway is one of the most
frequent molecular alterations in a wide variety of human can-
cers (30–34). Overexpression or inappropriate activation of
AKT1 is noted in many types of cancer.
Despite its importance in numerous signaling pathways, our
understanding of the activation and regulation of AKT kinases
is still incomplete. The lipid-binding PH domain of AKT plays
an important role in promoting the translocation of AKT to the
plasma membrane for activation. Recent results suggest that
the PHdomain is also important for the interactionwith a num-
ber of other proteins (35). In our recent effort to scan the
mRNA-displayed proteome libraries for Ca2CaM-binding
proteins, we found that both human and Caenorhabditis
elegansAKT1bound toCaM in aCa2-dependentmanner (2).4
Here we extend Dickson’s work and report that AKT1 inter-
acts with Ca2CaM through two binding motifs, one at the
first half of the N-terminal PH domain and another at the N
terminus of the kinase catalytic domain. Our results indicate
that Ca2CaM and AKT1 can be co-immunoprecipitated
and the Ca2CaM binding appears to be general in all three
AKT isoforms. The Ca2CaM binding to the N-terminal PH
domain of AKT1 could regulate its interaction with
PtdIns(3,4,5)P3.
EXPERIMENTAL PROCEDURES
Construction of Recombinant Genes and Expression of AKT1
Fragments—The cDNA corresponding to the open reading
frame of human AKT1 was reversibly transcribed from a
human poly(A) mRNA library (Ambion, Austin, TX). The
full-length AKT1 was amplified using a high fidelity Platinum
Pfx DNA polymerase (Invitrogen) with the following primers:
forward primer, 5-CACCATGAGCGACGTGGCTATT-
GTGA-3; reverse primer, 5-GGCCGTGCCGCTGGC-3.
The PCR product of full-length AKT1 was gel-purified and
cloned into a pcDNA3.1/V5-His TOPO vector (Invitrogen)
according to the manufacturer’s instructions. The resulting
AKT1-containing plasmid was confirmed by PCR and
sequence analysis. This construct was used as the template to
PCR-amplify various AKT1 fragments.
The synthesis of AKT1 fragments using coupled in vitro
transcription and translation (TNT) was performed as previ-
ously described (2). The primers for the generation of the
PCR products of these AKT1 fragments were as follows. For
the fragment F43–115, BD-HS43-5 (5-CAATTACTATTTA-
CAATTACAATGGGACAGGATGTGGACCAAC-3) and
BD-HS115-3 (5-TTAATGGTGATGGTGATGATGCTCC-
TCCTGCTTCTTGAGGC-3); for F116–149, BD-HS116-5
(5-CAATTACTATTTACAATTACAATGGGAGAGGAG-





GCCAC-3); for F198–408, BD-HS198-5 (5-CAATTACTAT-
TTACAATTACAATGGGAGAGAACCGCGTCC-3) and
BD-HS408-3 (5-TTAATGGTGATGGTGATGATGAAA-
GAAGCGATGCTGCATGATCTC-3); for F409–480, BD-
HS409-5 (5-CAATTACTATTTACAATTACAATGGGA-
GCCGGTATCGTGTG-3) and BD-HS480-3 (5-TTAATG-
GTGATGGTGATGATGGGCCGTGCCGCTGGC-3); for
F1–115, BD-HS1-5 (5-CAATTACTTTTACAATTACAAT-
GGGAAGCACGTGGCTATTG-3) and BD-HS115-3; for
F1–149, BD-HS1-5 and BD-HS149-3; for F1–408, BD-HS1-5
and BD-HS408-3; for F1–480, BD-HS1-5 and BD-HS480-3;
for F150–408, BD-HS150-5 and BD-HS408-3; for F150–480,
BD-HS150-5 and BD-HS480-3; and for F116–480,
BD-HS116-5 and BD-HS480-3.
Some fragments were also overexpressed and purified as
GST fusion proteins in Escherichia coli. The primers are: for
F1–42, HS-3-F (5-GACGACGACAAGATGAGCGACGTGG-
CTATTGTGA-3) and HS-3-R (5-GAGGAGAAGCCCGGT-
TTACGGCCGCTCCTGTAGC-3); for F1–115, HS-3-F and
HS-1-R (5-AGGAGAAGCCCGGTTTACTCCTCCTGCTT-
CTTGAGG-3); for F92–115, HS-1-F (5-GACGACGACAAG-
ATGACTCCTGAGGAGCGGG-3) and HS-1-R; for F116–197,
HS-2-F (5-GACGACGACAAGATGGAGGAGATGGACTT-
CCGG-3) and HS-2-R. The sequences corresponding to these
fragments were cloned into an expression vector pET-41
EK/LIC containing anN-terminal GST tag (Novagen,Madison,
WI). After confirmation of sequences, the insert-containing
plasmids were transformed into BL21(DE3)-competent cells
for expression of variousAKT1 fragments. Soluble protein frag-
ments were purified using glutathione-agarose beads (Santa
Cruz Biotechnology, Santa Cruz, CA) according to the manu-
facturer’s instructions.
Purified PH domain (residues 1–149), PH domain-deleted
AKT1 (residues 118–480, active), full-length human AKT1
(residues 1–480, both active and inactive), full-length AKT2,
and full-length AKT3 were purchased from Upstate (Char-
lottesville, VA). The PH domain-deleted AKT1 (residues 140–
480) from New England Biolabs (Ipswich, MA) was also used.
Cell Culture and Lysate Preparation—HeLa S3 cells were
grown to stationary phase in Ham’s F-12 medium supple-
4 X. Shen, C. A. Valencia, W. Gao, S. W. Cotten, B. Dong, M. Chen, and R. Liu,
submitted for publication.
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mented with 10% fetal bovine serum. Cells were harvested and
lysed as reported (36). After centrifugation to remove intact
cells, the supernatants were cleared at 14,000 rpm for 15min at
4 °C. Lysates prepared were used for pulldown assays and co-
immunoprecipitation experiments.
CaM Binding and Pulldown Assays—To investigate the
interaction between Ca2CaM and fragment/full length AKT,
CaM binding assays were performed using both radiolabeled
AKT protein fragments generated by TNT and GST-tagged
fragments overexpressed in E. coli. For the TNT approach,
radiolabeled AKT fragments were synthesized in the presence
of 10 Ci of [35S]methionine (PerkinElmer Life Sciences) in a
total volume of 25l for 90min at 30 °C as previously described
(2). To perform the CaM binding assays, an aliquot of the TNT
product was mixed with an appropriate amount of biotinylated
CaM for 90min at 4 °C in bufferA (25mMTris-HCl, pH8.0, 150
mM NaCl, 1 mg/ml bovine serum albumin, 5 mM 2-mercapto-
ethanol, 1mMCaCl2) or buffer B (same as buffer A except 1mM
CaCl2 was replaced with 2 mM EGTA). After binding, 30 l of
the 50% slurry of streptavidin beads (Pierce Biotech, Rockford,
IL) was added, and the mixture was incubated for 45 min at
room temperature with gentle mixing. The supernatant was
removed by centrifugation in anUltrafree-MC centrifugal filter
tube (Millipore, Billerica, MA), and the beads were washed
three timeswith 150l of bufferA. Proteins capturedwere then
released from the column by chelating Ca2 with 150 l of
buffer B. Each fractionwas separated by SDS-PAGE and images
were obtained through a Storm 860 PhosphorImager.
When GST-tagged, overexpressed AKT fragments or cell
lysates were used for the binding reaction, CaM-Sepharose
pulldown assays were performed. To do that, 100 l of pre-
equilibrated CaM-Sepharose 4B beads (Amersham Bio-
sciences) was added to an appropriate amount of purified AKT
protein (1–10 g), or HeLa S3 cell lysates (1 mg of total pro-
tein), followed by incubation at 4 °C for 2–3 h in a buffer con-
taining 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 EDTA-free
protease inhibitor mix, with 1 mM Ca2 (buffer C) or 2 mM
EGTA (buffer D). The beads were washed three times with
buffer C or buffer D. Proteins bound to CaM were eluted
from the beads with buffer D. Proteins from each fraction (L,
purified AKT protein or lysate; FT, flow-through; W, last
wash before elution; and E, elution) were resolved on SDS-
PAGE gels, transferred to a nitrocellulose membrane (Amer-
sham Biosciences), and probed with either anti-AKT1 (Santa
Cruz Biotechnology, Santa Cruz, CA), anti-His tag (R&D
Systems, Minneapolis, MN), anti-AKT (for all AKT iso-
forms, Cell Signaling Technology, Danvers, MA), or anti-
Calcineurin A2 (Santa Cruz Biotechnology).
Competitive Binding and Elution Assay—For competitive
binding experiments, 2 M GST-tagged PH domain of AKT1
(Upstate) was added to a binding mixture with the full-length
AKT1 pre-complexed with Ca2CaM immobilized on Sepha-
rose beads. The elution was performed with buffer B. For com-
petitive elution experiments, 2–50MPHdomain of AKT1 or a
CaM-binding peptide from MLCK (Ac-RRKWQKT-
GHAVRAIGRL-NH2) (Calbiochem) in buffer A was used to
elute the full-length AKT1 pre-complexed with Ca2CaM on
agarose beads.
CaM Binding Affinity Measurement—To measure the bind-
ing affinity of AKT fragments with Ca2CaM, the [35S]methi-
onine-labeled PH domain F1–149, F150–408, and full-length
AKT1 were generated by TNT and mixed with biotinylated
CaM,whose concentrationwas varied in the range of 10 nM and
2.5 M. Biotin-CaMprotein complex was captured by strepta-
vidin beads, and the extent of binding was determined by scin-
tillation counting of each fraction, followedby fitting the data to
a binding curve using SIGMAPLOT 8.0 software (Systat, Rich-
mond, VA).
Immunoprecipitation and Co-immunoprecipitation—Im-
munoprecipitation was performed by incubating 1 mg of HeLa
S3 lysate with anti-CaM, anti-AKT1, or an irrelevant IgG,
respectively. Samples were separated by SDS-PAGE, trans-
ferred to a nitrocellulose membrane, and probed with different
antibodies.
For co-immunoprecipitation experiments, equal amounts of
pre-cleared HeLa S3 whole cell lysate (1 mg of total protein)
were incubated with 2–5 g of primary antibody (anti-CaM)
for 4 h at 4 °C, in the presence of either buffer C or buffer D. 20
l of pre-equilibrated protein A/G-agarose conjugate was
added, and the mixture was further incubated at 4 °C for 2 h
withmixing. The pellets were collected and washed three times
with buffer C orD. After the final wash, pellets were elutedwith
buffer D. Different fractions were loaded onto SDS-PAGE fol-
lowed byWestern blotting and probing using anti-AKT1. Con-
versely, anti-AKT1 was used for co-immunoprecipitation and
blots were probed with anti-CaM. As a positive control, blots
were probed with anti-Calcineurin A2, for the detection of cal-
cineurin, a well known CaM-binding protein. As a negative
control, blots were also probed with an irrelevant anti-TFII
antibody.
Protein Lipid Overlay Assay—PtdIns(3,4,5)P3, PtdIns(3,4)P2,
PtdIns(3,5)P2, PtdIns(4,5)P2, and phosphatidylcholine were
obtained from Echelon Biosciences (Salt Lake City, UT). 100
pmol of each PIP were dotted on a Hybond-C Extra membrane
(Amersham Biosciences), and protein lipid overlay assay was
performed according to the manufacturer’s instructions. Dif-
ferent amounts of PtdIns(3,4,5)P3 were also used to examine its
concentration dependence. The membrane was first blocked
for 1 h in a TBS buffer (25 mM Tris-HCl, pH 8.0, 150 mMNaCl)
with 0.1% (v/v) Tween 20 and 3% (w/v) bovine serum albumin.
It was then incubated at 4 °C overnight with 0.5 g/ml His-
tagged full-length AKT1 (Upstate), GST-tagged PH domain of
AKT1 (Upstate), or His-tagged AKT1 without PH domain
(Upstate) in the blocking buffer containing 0.24 M CaM and
100 M Ca2 or EGTA. After washing three times, the mem-
brane was incubated with anti-His tag or anti-GST for 3 h at
room temperature. Themembranewas washed again and incu-
bated with anti-mouse IgG horseradish peroxidase (Amersham
Biosciences), followed by development using ECLplusWestern
blotting detection system (Amersham Biosciences).
RESULTS
To address the difficulty of identifying the numerous condi-
tional interactions that are dependent on the intracellular Ca2
concentrations, we developed an mRNA-display protein selec-
tion platform that allows us to scan a proteome of interest for
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Ca2-dependent protein-protein interactions (2).4 By employ-
ing this novel approach, we have scanned both the human and
the C. elegans proteomes for Ca2CaM-binding proteins (2).4
A large number of both known and previously uncharacterized
Ca2CaM-binding proteins were identified, including many
protein kinases. These CaM-binding kinases include CaM-de-
pendent protein kinase, CaM-dependent protein kinase kinase,
elongation factor kinase, and protein kinase C family member
UNC-13 that have been previously characterized to interact
with Ca2CaM (37). Several protein kinases that have not been
previously reported to interact with Ca2CaMwere also iden-
tified, and AKT1 is among them. The discovery that both
human and C. elegans AKT1 kinases interact with CaM in a
Ca2-dependentmanner strongly suggests thatCa2CaMplay
an important role in regulating the functions of AKT.
We first characterized the interaction of Ca2CaM with
AKT1 by sequence analysis of the selected fragments. Only one
fragment originating from human AKT1 was isolated in the
Ca2CaM-binding selection using an mRNA-displayed
human proteome library. Sequence analysis showed that this
was a fragment that covered the entire PH domain of human
AKT1. However, four fragments originating from C. elegans
AKT1 were isolated, namely, F1–144, F54–138, F105–138, and
F103–172 (Fig. 1). All these fragments are located within or close
to the PHdomain ofC. elegansAKT1. F1–144 contains thewhole
PH domain (the arrowed region), whereas F54–138 contains its
second half. The shortest overlapping region is between resi-
dues 105 and 138 (105VRQRWIHAIESISKKYKGTNAN-
PQEELMETNQQP138). This region covers the C-terminal part
of the PH domain and part of the LINK region. Using a web-
basedmotif analysis program (37), it is found that this fragment
contains a positively charged amphiphilic -helix (underlined),
which is a characteristic of many Ca2CaM binding motifs.
To investigate the interaction of these fragments with CaM,
we generated radiolabeled AKT fragments by TNT and used
them in the CaM binding assay in the presence or absence of
Ca2. We first validated the assay using both positive and neg-
ative controls. For positive controls, more than 20 well known
human Ca2CaM-binding proteins or their fragments con-
taining the Ca2CaM bindingmotifs were synthesized by TNT
and used to test their CaM binding with this assay. It was found
that all these positive controls bound to CaM specifically in a
Ca2-dependent manner (data not shown). For negative con-
trols, a number of proteins or their fragments that have never
been reported to interact with CaM were used. In addition,
several knownCa2CaM-binding proteinswith theCa2CaM
binding motifs deleted were also used as negative controls. No
binding was detected for these negative control proteins under
the conditions used in such in vitro assay, as shown in Fig. 2
using SNAP25 as an example. The results of both positive and
negative controls demonstrate this CaM binding assay is a very
robust method to elucidate protein interactions with
Ca2CaM. Using this CaM binding assay, it was found that all
the four selected C. elegans AKT fragments bound to CaM in a
Ca2-dependent manner as shown in Fig. 2, and the binding
was completely abolished when Ca2 was chelated with EGTA.
When irrelevant proteins such as SNAP25 were used as nega-
tive controls, no CaM binding was observed. Interestingly,
F54–138, a fragment that covers both the second half of the PH
domain and the LINK region, bound to Ca2CaM very tightly,
implying it contains at least one of the major binding motifs. It
appears that the interaction of Ca2CaMwith the longer frag-
ment F1–144 was not as strong as that with F54–138 or F105–138.
This phenomenon was also observed in the interaction of CaM
with a number of other proteins (2), presumably because the
CaM binding motifs are more accessible when present as short
fragments.
Because the antibodies for C. elegans AKTs are not readily
available, we focused our investigation on human AKTs. We
hypothesized that human AKTs should use different region(s)
at or close to the PH domain to interact with Ca2CaM, pre-
sumably because the LINK region of C. elegans AKT1 has very
low sequence homology with human AKT1 (supplemental Fig.
S1). Tomap the location of theCaMbindingmotif(s) on human
AKT1, we generated by TNT [35S]methionine-labeled protein
fragments that cover all the possible regions of AKT1 (Fig. 3).
FIGURE 1. Schematic presentation of the Ca2CaM-binding AKT1 frag-
ments selected from an mRNA-displayed C. elegans proteome library.
The region of the PH domain of C. elegans AKT1 is indicated with arrows.
FIGURE 2. In vitro Ca2CaM binding of AKT1 fragments selected from an
mRNA-displayed C. elegans proteome library. [35S]Methionine-labeled
protein fragments were generated by TNT. An aliquot of the TNT reaction
mixture was incubated with an appropriate amount of biotinylated CaM in
the presence or absence of Ca2, followed by mixing with streptavidin-agar-
ose beads. The beads were washed, and the bound proteins were eluted
using a buffer containing EGTA. Each fraction was separated by SDS-PAGE,
and images were obtained by autoradiography. Numerous positive and
negative controls were performed but only SNAP25 was shown here as a
negative control. L, TNT product; FT, flow through; W, last wash before
elution; and E, elution.
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Specifically, F1–115 covers the PH domain, F116–149 the LINK
region, F150–408 the kinase catalytic domain, and F409–480 the
C-terminal extension domain, respectively. Consistentwith the
result from the selection using an
mRNA-displayed human proteome
library, the PH domain of AKT1
(residues 1–115) bound toCaMwell
(Fig. 4A). This interaction is highly
dependent on the presence of Ca2.
When EGTA was included, the
binding was completely abolished.
All the fragments that contain the
PH domain, including F1–149,
F1–408, and F1–480, also bound to
CaM in a Ca2-dependent manner
(Fig. 4A). We further mapped the
binding motif within the PH
domain using F1–42 and F43–115 that cover two different parts of
the PH domain. It appeared that the Ca2CaM binding of the
PH domain of AKT1 could be attributed to the first 42 residues,
because F1–42 strongly bound to Ca2CaM, whereas F43–115
showed no binding at all (Fig. 4B).
We then examined whether the PH domain-deleted AKT1
also interacted with Ca2CaM. Surprisingly, F116–480 also
bound to Ca2CaM (Fig. 4A), suggesting the presence of
another CaMbindingmotif. Tomap this second bindingmotif,
three protein fragments that cover the LINK region (F116–149),
the kinase catalytic domain (F150–408), and the C-terminal
extension domain (F409–480), respectively, were generated and
used to interact with CaM. Interestingly, it was found that this
second CaM-binding site was not in the LINK or the C-termi-
nal extension regions, but within the kinase catalytic domain.
We further mapped this CaM binding motif to F150–197 (Fig.
4B), a region at the N terminus of the kinase catalytic domain.
Indeed, all the fragments that contain F150–197 also bound to
Ca2CaM, including F150–408, F150–480, and F116–480 (Fig. 4A).
As already shown in Fig. 2, negative control proteins did not
bind to CaM in these assays.
The results using TNT-generated protein fragments were
consistentwith theCaM-Sepharose pulldown assay usingGST-
tagged proteins overexpressed in E. coli (supplemental Fig. S2).
To rule out the possibility of nonspecific interaction due to the
presence of GST tag in such a pulldown assay, overexpressed
GST tag alonewas used in the binding.Nobindingwas detected
betweenGST tag andCaM, both in the presence and absence of
Ca2. Taken together, our results suggest that there exist two
Ca2CaMbindingmotifs on humanAKT1, one at the first half
of the PH domain (F1–42) and the other at theN terminus of the
kinase catalytic domain (F150–197).
To analyze the interaction quantitatively, we determined the
binding affinity of these two fragments of AKT1 with
Ca2CaM by varying the concentration of biotinylated CaM
used in the CaM binding assay. The binding affinity for F1–149
andF150–408was750 100nMand500 80nM, respectively.
The full-length AKT1 has an affinity similar to that of these
fragments. This relatively weak interaction suggests that each
bindingmotifmight require the elevation of local Ca2 concen-
tration to effectively compete with many other CaM-binding
proteins in vivo.
To investigate the interaction betweenAKT1 andCa2CaM
under physiological conditions, we first tested whether the
FIGURE 3. Schematic diagram of the overexpressed human AKT1 fragments used in mapping the
Ca2CaM binding motifs. Different regions on full-length human AKT1 are indicated with arrows. A, list of
fragments that are relatively longer; B, list of fragments that are shorter.
FIGURE 4. In vitro CaM binding assays using different human AKT1 frag-
ments. All the fragments were generated by TNT, except F1– 42, which could
not be TNT-synthesized and was obtained by overexpression in E. coli. For
TNT-generated fragments, an appropriate amount of [35S]methionine-la-
beled AKT1 fragment was incubated with biotinylated CaM in a buffer con-
taining either Ca2 or EGTA. The beads were washed, and the bound mole-
cules were eluted using a buffer containing EGTA. The fragments were
separated by SDS-PAGE and detected by autoradiography. For F1– 42, the pull-
down assay was performed with CaM-Sepharose in the presence of either
Ca2 or EGTA as detailed under “Experimental Procedures.” F1– 42 was
detected by Western blot analysis using anti-GST. L, AKT protein fragment; FT,
flow-through; W, last wash before elution; and E, elution. A, list of fragments
that are relatively longer; B, list of fragments that are shorter.
Interaction between Ca2/CaM and the PH Domain of AKT1
AUGUST 24, 2007 • VOLUME 282 • NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 25135
endogenous AKT1 could be pulled down by CaM-Sepharose.
Fig. 5 shows that the AKT1 from human HeLa cells complexed
withCaM in aCa2-dependent fashion.WhenEGTAwas pres-
ent in the pulldownbuffer, the binding ofAKT1 toCaM-Sepha-
rose was totally disrupted. As a positive control, a well known
CaM-binding protein, calcineurin, was shown to bind to CaM
through the pulldown assay. We further investigated whether
the interaction exists in vivo by co-immunoprecipitation when
both CaM and AKT1 are present at their physiological concen-
trations. Fig. 6A illustrates that AKT1 was co-immunoprecipi-
tated with CaM when anti-CaM antibody was used for the
immunoprecipitation. As a positive control, calcineurin was
found to be co-immunoprecipitated with CaM as previously
reported. As a negative control, we checked an irrelevant TFII
protein and found it was not co-immunoprecipitated with
CaM. Conversely, CaM was co-immunoprecipitated with
AKT1 when anti-AKT1 was used in the immunoprecipitation
(Fig. 6B). We also performed immunoprecipitation using an
IgG and could not detect the presence of CaM or AKT1 by
probing the Western blots using corresponding antibodies
(data not shown). These results indicate that the
AKT1Ca2CaM complex is present in vivo. Since direct bind-
ing of AKT1 with CaM has been detailed in vitro, the observed
interaction with CaM is most likely to be direct rather than
mediated by other proteins.
To investigate the possible role ofCaM-binding onAKT1,we
first examined whether the CaM binding motif near the N ter-
minus of the kinase catalytic domain affects its kinase activity.
To address this question, the phosphorylation of biotinylated
cross-tide catalyzed by either active or inactive recombinant
human AKT1 was performed in the presence of [-32P]ATP.
The kinase was preincubated with Ca2, Ca2CaM, or EGTA/
CaM, respectively, before being used in the phosphorylation
reaction. RecombinantAKT1 proteins with PHdomain deleted
were also used in the assay. No change of phosphorylation was
detected when Ca2CaM was present (data not shown), indi-
cating the catalytic activity of AKT1 is not regulated by CaM.
We then focused on examining the CaMbindingmotif at the
PH domain of AKT1. To address this question, we investigated
whether the interaction between Ca2CaM and the full-length
AKT1 could be disrupted by the free PH domain of AKT1.
Although the three-dimensional structure of the full-length
AKT has not yet been reported, there exist several structures
for the separate AKT and the PH domain (8, 38–41). It was
modeled that the C-terminal helix of the PH domain extends
about three turns beyond the consensus core, implying a well
separated PH domain from the AKT catalytic region (8). We
hypothesized that if the PH domain of AKT directly interacts
with Ca2CaM, the formation of the AKTCa2CaM complex
should be disrupted when a free PH domain of AKT is included
in the binding mixture. Indeed, compared with that when no
PH domain was added (Fig. 7A, panel 1), the amount of full-
length AKT1 that could be pulled-down by CaM-Sepharose
was significantly decreased when free PH domain was included
in the binding buffer (Fig. 7A, panel 3), similar to that when the
interaction was completely disrupted by chelating Ca2 with
EGTA (Fig. 7A, panel 2). This was presumably due to compet-
itive binding from the externally added PH domain with CaM.
Furthermore, it was found that the full-length AKT1 pre-com-
plexed with Ca2CaM could be eluted when an excess amount
of free PH domain was used to replace EGTA in the elution
FIGURE 5. Pulldown assay of endogenous AKT1 from HeLa S3 cell
lysate using CaM-Sepharose. The lysate was incubated with CaM-Sepha-
rose 4B beads in the presence of either 1 mM CaCl2 or 2 mM EGTA. The
beads were washed, and the bound proteins were eluted with a buffer
containing EGTA. Western blots were probed with anti-AKT1 for the pres-
ence of AKT1 or with anti-Calcineurin A2 for the presence of calcineurin as
a positive control. L, lysate; FT, flow-through; W, last wash before elution;
E, elution.
FIGURE 6. Co-immunoprecipitation of endogenous AKT1 from HeLa S3
cell lysate with CaM. Equal amounts of pre-cleared HeLa cell lysate were
incubated with anti-CaM or anti-AKT1 antibody in the presence of either 1 mM
CaCl2 or 2 mM EGTA. The protein complex was captured by protein A/G-aga-
rose conjugate and eluted with a buffer containing EGTA. A, co-immunopre-
cipitation with anti-CaM. Proteins associated with CaM were detected by
Western blot analysis using anti-AKT1, anti-Calcineurin, and anti-TFII for
AKT1, positive control protein (CALNA), and negative control protein (TFII),
respectively. B, co-immunoprecipitation with anti-AKT1. CaM associated with
AKT1 was detected by probing the Western blot with anti-CaM. C, immuno-
precipitation controls showing that anti-CaM can capture CaM and anti-
AKT1 can capture AKT1. L, lysate (not loaded proportionally); FT, flow-
through; W, last wash before elution; E, elution.
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buffer (Fig. 7B, panel 1). Significantly, a high concentration of
free PH domain (20 M) was required to elute the full-length
AKT1, implying that the AKT1Ca2CaM complex is very sta-
ble once formed or that the secondCaMbinding site is contrib-
uting to the stabilization of the complex.
Although the amino acid sequences of the Ca2CaM bind-
ing motifs in numerous CaM-binding target proteins are
extremely diverse, many Ca2CaM-binding proteins have one
or more CaM-binding regions that are characterized by a basic
amphipathic helix with 20 amino acids in length, as that
structurally detailed in myosin light chain kinase (MLCK) (37,
42). To determine if the PH domain of AKT1 competes with
other CaM-binding proteins for the same binding region(s) on
CaM, a short peptide from the CaM binding motif of MLCK
was used to compete with full-lengthAKT1 in Ca2CaMbind-
ing assay. This peptide was known to bind to Ca2CaM with
very high affinity (Kd  6 pM) (43). Surprisingly, unlike the PH
domain, this Ca2CaM-binding peptide could not competi-
tively eluteAKT1 from its complex pre-formedwithCa2CaM
(Fig. 7B, panel 2), indicating that the PH domain of AKT1 bind
to Ca2CaM at regions that are different from the conven-
tional sites.
The PH domain of AKT is highly conserved among the three
AKT isoforms (supplemental Fig. S3). Therefore, we examined
whether other human AKT isoforms also interact with CaM in
a similar fashion. Fig. 8 illustrates that CaM generally binds to
AKT family members, including AKT2 and AKT3 in a Ca2-
dependent manner. Significantly, all the binding with CaMwas
completely abolished when EGTA was used to chelate Ca2,
indicating that Ca2CaM complex is necessary for the
observed interactions. Because the first 42 residues of the PH
domain ofAKT isoforms are74% identical (supplemental Fig.
S3), it is likely that all three AKT isoforms interact with
Ca2CaM at the same regions through similar mechanism.
The major role of the PH domain of AKT is to recruit AKT
from cytosol to plasma membrane through its interaction with
PtdIns(3,4,5)P3. To address whether the interaction with
Ca2CaM affects the phosphoinositide-binding property of
the PH domain of AKT, we first examined the complex forma-
tion between the PH domain of AKT1 and Ca2CaM in the
presence or absence of a phosphoinositide. Itwas found that the
amount of the PH domain that could be pulled down by CaM-
Sepharosewas decreased60%whenPtdIns(3,4,5)P3was pres-
ent (data not shown), implying that Ca2CaM and
PtdIns(3,4,5)P3 directly compete for the PH domain of AKT.
We further investigated whether the presence of Ca2CaM
disrupted the interaction between the PH domain of AKT and
various phosphoinositides, using a protein lipid overlay assay.
To this end, a strip membrane spotted with 100 pmol of each
PIP was used for the protein lipid overlay experiment with var-
ious amounts of full-length AKT1, the PH domain of AKT1,
and AKT1 with PH domain deleted. Fig. 9A illustrates that the
interactions between the PH domain of AKT1 and various
phosphoinositides, including PtdIns(3,4,5)P3,PtdIns(3,4)P2,
FIGURE 7. Competitive binding and competitive elution assays. A, com-
petitive binding between CaM, full-length human AKT1 and PH domain of
AKT1. 1 mM Ca2 was included in the binding buffer (BB) to facilitate CaM
binding (panels 1 and 3). 2 M of the PH domain of AKT1 was added to the
binding reaction mixture to compete with the full-length AKT1 for
Ca2CaM binding (panel 3). Panel 2 is a negative control in which the CaM
binding was abolished by including EGTA in the binding buffer. Full-length
AKT1 was eluted from CaM-Sepharose 4B beads with an elution buffer (EB)
containing 0.5 mM EGTA. L, full-length AKT1 protein (not loaded proportion-
ally); FT, flow-through; W, last wash before elution; E, elution. B, competitive
elution of full-length AKT1 pre-complexed with Ca2CaM using the PH
domain of AKT1 or MLCK peptide. Full-length AKT1 was first complexed with
CaM on Sepharose 4B beads in the presence of Ca2. The bound AKT1 was
then eluted by the PH domain of AKT1 (first panel) or MLCK peptide (second
panel) twice with increased concentrations. L, full-length AKT1 protein (not
loaded proportionally); FT, flow-through; W, last wash before elution; E1, first
elution with 2 M of PH domain of AKT1 or MLCK peptide; E2, second sequen-
tial elution with 20 M of PH domain or MLCK peptide. Full-length AKT1 was
detected by Western blot analysis using anti-AKT1.
FIGURE 8. In vitro CaM-Sepharose pulldown assay using His-tagged full-
length AKT1, AKT2, and AKT3. The pulldown assays were performed in the
presence of either Ca2 or EGTA. The AKT kinases were detected by Western
blot analysis using anti-His tag. L, full-length AKT protein (not loaded propor-
tionally); FT, flow-through; W, last wash before elution; E, elution with EGTA.
FIGURE 9. Protein lipid overlay assay. A, inhibition of the interaction of the
PH domain of AKT1 with various phosphoinositides by Ca2CaM. 100 pmol of
each PIP was dotted on Hybond-C Extra membranes and pre-blocked with
bovine serum albumin in TBS buffer. PIP strips were incubated with His-
tagged full-length AKT1, GST-tagged PH domain of AKT1, or His-tagged AKT1
without PH domain in the presence of Ca2, EGTA/CaM, or Ca2CaM, respec-
tively. The proteins bound to the immobilized phosphoinositides on the
membrane were detected using anti-His tag or anti-GST as the primary anti-
body and anti-mouse IgG-horseradish peroxidase as the secondary antibody.
1, PtdIns(3,4,5)P3; 2, PtdIns(3,4)P2; 3, PtdIns(4,5)P2; 4, PtdIns(3,5)P2; 5, phos-
phatidylcholine; 6, blank. B, inhibition of the interaction of the PH domain of
AKT1 with various concentrations of PtdIns(3,4,5)P3 by Ca
2CaM. The con-
centrations of PtdIns(3,4,5)P3 dotted on the membrane were 200 pmol (lane
1), 100 pmol (lane 2), 50 pmol (lane 3), 25 pmol (lane 4), 13 pmol (lane 5), 6.3
pmol (lane 6), 3.2 pmol (lane 7), 1.6 pmol (lane 8), and 0 pmol (lane 9),
respectively.
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PtdIns(4,5)P2, and PtdIns(3,5)P2, were significantly reduced
whenCa2CaMwas included in the binding buffer. Such inter-
ruption of interaction between AKT1 and PIP was dependent
on the concentrations of CaM used in the overlay assay (data
not shown). The overlay assaywas performed several times, and
results were reproducible. The inhibition by Ca2CaM to each
PIP was quantitatively analyzed by averaging the results from
different overlay assays. For PtdIns(3,4,5)P3, Ca2CaM treat-
ment lowered the full-length AKT1 binding from 100 to 20%
when compared with EGTA/CaM treatment blot. Such inter-
action was not due to calcium, because there is no significant
difference between Ca2 and EGTA/CaM treatments in terms
of the amount of full-length AKT1 binding to PtdIns(3,4,5)P3.
For PtdIns(3,4)P2, the addition of Ca2CaMdecreased the full-
length AKT1 binding to 20% of EGTA/CaM and Ca2 treat-
ments. When the PH domain of AKT1 was used in the lipid
overlay assay, its binding to PtdIns(3,4,5)P3 decreased from
100% to 30%with the addition of Ca2CaM. Only20% of the
PH domain of AKT1 bound to PtdIns(3,4)P2 in the presence of
Ca2CaM, compared with that with EGTA/CaM. Interest-
ingly, PH domain of AKT1 bound to PtdIns(4,5)P2, but the
binding was reduced to only 10% after the addition of
Ca2CaM. No significant difference in terms of the amount of
PH domain of AKT1 bound to each of the lipids was observed
between EGTA/CaM- and Ca2-treated samples. Consistent
with the findings reported in the literature, the interaction of
AKT1 with phosphoinositides is PH domain-dependent, and
was completely abolished when the PH domain was deleted
from AKT1 protein (Fig. 9, panel 3). These results demon-
strated that the interaction between the PH domain of AKT1
and phosphoinositides could be conditionally disrupted by
CaM when the concentration of Ca2 is elevated. We further
examined the inhibition of the binding of the PH domain of
AKT1 to a dilution series of PtdIns(3,4,5)P3 by Ca2CaM. As
shown in Fig. 9B, the inhibition is highly dependent on the
PtdIns(3,4,5)P3 concentrations. Although the interaction of the
PH domain of AKT1 with PtdIns(3,4,5)P3 was still clearly
detected when PtdIns(3,4,5)P3 was used at 13 pmol, the inter-
action was significantly inhibited by Ca2CaM in the whole
concentration range.
DISCUSSION
Among a number of Ca2 sensors in the eukaryotic cell, CaM
is themostwidespread and the best studied. CaM interactswith
many different protein targets and mediates a wide variety of
cellular functions. Most CaM-mediated signaling pathways are
through the Ca2CaM complex, which is highly modulated by
intracellular Ca2 concentration (44–49). Two distinct CaM
binding motifs on AKT1 were thoroughly mapped using pro-
tein fragments that cover all the possible regions of AKT1. In
addition, those regions that contain a CaM binding motif were
carefully examined usingmultiple smaller fragments, to further
determine the location of the CaM binding motifs. Taken
together, the observed CaM binding can be attributed to two
well definedCaM-binding regions, one at the first half of the PH
domain (F1–42) and the other near the N terminus of the kinase
catalytic domain (F150–197). We found that all the fragments
that contain one of the mapped CaM binding motifs bound to
CaM in a Ca2-dependent manner, whereas all the fragments
that contain none of themappedCaMbindingmotifs could not
interact with CaM. Therefore, such CaM binding is less likely
due to nonspecific interaction. Indeed, it is not unusual that
CaM-binding proteins contain more than one CaM-binding
domain, and the interactions of these proteins to CaM are well
known to be specific (37). The presence of a second CaM bind-
ingmotif near theN terminus of the catalytic domain of human
AKT1 is intriguing. It appears that C. elegans AKT1 also con-
tains a Ca2CaM binding motif close to this region. However,
the exact location is different from that on human AKT1.
Therefore, it is likely that AKT proteins from different species
are regulated by Ca2CaM at close but not identical regions. It
is also possible that this is not a function that has been con-
served in C. elegans. The significance of the Ca2CaM binding
motif near theN terminus ofAKT1 catalytic domain remains to
be determined. We found that the catalytic activity of human
AKT1 was not affected by Ca2CaM. We postulate that the
Ca2CaM regulation affects the activation or subcellular loca-
tion of AKT1, rather than the kinase activity of the enzyme
directly.
The PH domain of AKT has a -barrel shape that is closed at
one end by the C-terminal -helix, whereas at the other end lie
three loops that are variable, both in sequence and length, in all
known PH domains (39). These loops form a highly basic
pocket intowhich the 3- and 4-phosphates of PtdIns(3,4)P2 and
PtdIns(3,4,5)P3 can bind. Specifically, before the binding of the
lipid, the ligand-binding pocket in the PH domain is occupied
by a complex hydrogen bonding network. Upon binding of a
lipid such as Ins(1,3,4,5)P4, this network of hydrogen bonding is
disrupted. In the 1–42 region, Tyr-18 moves away from the
ligand-binding pocket to create space for the 5-phosphate,
Glu-17 moves outwards to enable the contact of Arg-86 with
the 4-phosphate, and Arg-23 moves inwards to make contact
with the 1- and 3-phosphates. As for the residues close to the
1–42 region, a short acidic patch is formed through the clus-
tering of three negatively charged residues (Asp-44, Asp-46,
and Glu-49) upon ligand binding.We found that the binding of
the PH domain of AKT1 could be in part attributed to residues
1–42 (Fig. 4). Because this region and its adjacent residues are
critical in lipid ligand recognition, it is not surprising that the
relatively weak interaction between the PHdomain of AKT and
the lipid ligands could be disrupted by Ca2CaM.
The PH domain is 80% identical among the AKT isoforms,
implying that other AKT isoforms also bind to Ca2CaM sim-
ilar to AKT1. Indeed, AKT2 and AKT3 appear to interact with
CaM in a manner that is highly dependent on Ca2. These
results indicate that the interaction betweenCa2CaMand the
PH domain of AKT is not just limited to AKT1, but could be
generally applied to all the three isoforms of AKT kinase. PH
domains are found inmany proteins involved in cellular signal-
ing (50). However, AKT was the only PH domain-containing
protein isolated from our Ca2CaM-binding selections using
mRNA-displayed proteome libraries.
Our finding that AKT1 is a Ca2CaM-binding protein
implies that the activity and functions of AKT1 are directly
regulated by the calcium signal. It is well known that the acti-
vated AKT1 is released from the plasma membrane to switch
Interaction between Ca2/CaM and the PH Domain of AKT1
25138 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282 • NUMBER 34 • AUGUST 24, 2007
on or off a large number of signaling pathways. Themechanism
of translocation of AKT1 to the plasma membrane for activa-
tion is well understood. Recently, the mechanism of deactiva-
tion of already activated AKT in cytosol was also revealed. It
was found that PH domain leucine-rich repeat protein phos-
phatase could terminate already activated AKT by the dephos-
phorylation of its hydrophobic motif (51).
One question that has not yet been addressed is how the
activated AKT is released or detached from the plasma mem-
brane after activation by phosphorylation (55–57), and once
detached, how to prohibit the activated AKT from re-associa-
tion with PtdIns(3,4,5)P3 on the plasmamembrane. It is known
that the level of PtdIns(3,4,5)P3 on the plasma membrane is
under control of lipid phosphatases, including SH2 domain-
containing inositol 5-phosphatase 2 and phosphatase and
tensin homolog deleted on chromosome 10, that convert
PIP3 back to PIP2 (52–54). Presumably, SH2 domain-con-
taining inositol 5-phosphatase 2 and phosphatase and ten-
sin homolog deleted on chromosome 10 can only regulate
the level of PtdIns(3,4,5)P3 that are unbound to the PH
domain, because it is difficult to understand how the already
bound PtdIns(3,4,5)P3 that forms extensive interactions with
the PH domain of AKT could be accessed and further
dephosphorylated by these lipid phosphatases. It is also
known that the PH domain of AKT1 is not required for its
activation or phosphorylation on Thr308 and Ser473. Con-
versely, based on the structural models of the full-length
AKT, it is unlikely that the phosphorylation of two conserved
residues at the well separated catalytic and extension
domains of AKT significantly alters its interaction with
PtdIns(3,4,5)P3. The interactions between inositol phos-
phates and phosphoinositides to the PH domain of AKT
have been investigated extensively (58–60). To understand
the detachment of activated AKT from the plasma mem-
brane, Hemmings and coworkers (57) proposed that the acti-
vated AKT might be detached from the membrane by com-
petitive binding of inositol triphosphates such as
Ins(1,4,5)P3. However, it is known that Ins(1,4,5)P3 binds to
the PH domain of AKT with 3- to 5-fold lower affinity than
PtdIns(3,4)P2 or PtdIns(3,4,5)P3, and other inositol phos-
phates bind to the PH domain at even lower affinities (58).
Therefore, it is difficult to understand how the inositol
triphosphate alone could efficiently detach the activated
AKT from the plasma membrane.
Our finding that Ca2CaM competes with PtdIns(3,4,5)P3
and PtdIns(3,4)P2 for interaction with the PH domain of AKT
suggests a general mechanism of the regulation of AKT activa-
tion by CaM-mediated calcium signals. We propose that the
membrane-bound AKT1 could be released from the plasma
membrane and/or the released AKT could be further prohib-
ited from re-association with PtdIns(3,4)P3 on plasma mem-
brane by CaMwhen local Ca2CaM concentration is elevated.
Because the intracellular concentration of Ca2-free CaM is
high (47), this detachment process is likely coupled with the
release ofCa2 from intracellular storage by Ins(1,4,5)P3, which
results in a significant increase of local Ca2CaM concentra-
tion. Unlike inositol phosphates and phosphoinositides that
bind to their targets weakly, Ca2CaM strongly interacts with
its targets, typically at a nanomolar scale. Although the affinity
of the PH domain with Ca2CaM reported here is 750 nM,
the interaction is still stronger than that with Ins(1,4,5)P3.
Indeed, it appears that the AKT-Ca2CaM complex is very
stable once formed (Fig. 7B, panel 1). Therefore, Ca2CaM
could efficiently detach the activated AKT from the plasma
membrane or/and lock the PH domain of AKT to prohibit it
from re-association with less abundant PtdIns(3,4,5)P3 or
abundant PtdIns(3,4)P2 on the plasma membrane.
In this report, we demonstrate that Ca2CaM directly and
specifically interacts with the PH domain of AKT1 under in
vitro conditions. The fact that AKT1 could be co-immunopre-
cipitatedwith CaM in aCa2-dependentmanner indicates that
the AKT1/Ca2CaM complex is present in vivo under physio-
logical conditions. This work is an extension of that reported by
Dickson and coworkers. Although we did not show that mod-
ulation of intracellular calcium affects AKT activity under
physiological conditions, the original report demonstrated that
EGF-induced AKT1 activation and survival in transgenic
mouse mammary tumor virus-c-Myc mouse mammary carci-
noma cells were both Ca2CaM-dependent (1). Interestingly,
such activation was mediated neither by CaM kinases nor by
phosphatidylinositol 3-kinase, but was rather abolished by
the intracellular Ca2 chelator BAPTA-AM and by the spe-
cific CaM antagonist W-7. Furthermore, the AKT1 activa-
tion by serum and insulin was also inhibited byW-7, suggest-
ing that the role of Ca2CaM in the activation of AKT1
could be general and irrespective of upstream receptor acti-
vator, mammalian species, and transformation status. Such
inhibition of AKT1 activation by intracellular Ca2 chelator
and specific CaM antagonist provided direct and strong evi-
dence that the modulation of intracellular Ca2 affects
AKT1 activity under physiological conditions. These in vivo
observations are consistent with our findings and support
the hypothesis that Ca2CaM regulates the function of AKT
through interacting with its N-terminal PH domain. How-
ever, more in vivo work is crucial to further confirm this
hypothesis in the cellular context.
AKT kinases are involved in numerous signaling pathways
and regulated by different mechanisms. In addition to its inter-
action with PtdIns(3,4,5)P3 to promote the translocation of the
kinase to the plasma membrane, the PH domain of AKT also
functions as a protein-protein interaction motif. It has been
reported that the PH domain of AKT is involved in the oli-
gomerization of AKT and is also important for interaction with
a number of other proteins that are involved in the regulation of
AKT, including TCL1, JIP1, Grb10, and RasGAP (3, 35). It will
be interesting to investigate whether these AKT/regulatory
protein interactions mediated by the PH domain are also mod-
ulated by Ca2CaM.
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